Medical · Georgia · November 13, 2026
Georgia medical cannabis changes that took effect July 1 are helping some veterans, including retired Marine Jason Quinn, who lives with a mild traumatic brain injury, PTSD and chronic pain after a 2010 IED blast. Quinn says legal cannabis calmed him and restored his skateboarding. A certifying doctor says new flower vapes work fast but suit only some veterans.
Why it matters: Georgia's switch from low THC oil to a broader medical program gives registered patients more product choices, including vapes that act quickly. Doctors quoted here stress that cannabis is not for everyone, that a physician must evaluate patients before they buy, and that it does not replace counseling or existing prescriptions. Patients should expect screening, not easy access.
Read moreSource: cbsnews.com
Medical · California · November 13, 2026
Cannabis consumers trust dispensary staff and healthcare providers far more than government for cannabis information, according to a new survey of 1,023 adults. Researchers from UC San Francisco and Johns Hopkins asked respondents to rate sources from 1 to 5. State and federal officials ranked near the bottom, and social media users ranked last.
Why it matters: Most consumers get guidance on dosing, effects and medical use from budtenders and clinicians, not from public agencies. That puts real weight on the training and accuracy of dispensary staff and doctors. It also suggests government safety messaging on cannabis may struggle to reach the people it targets, since many consumers discount it.
Read moreSource: norml.org
Medical · November 13, 2026
A survey of emergency room doctors and nurses in Canada finds strong support for medical cannabis. Published in BMC Emergency Medicine, it shows 96 percent want eligible patients to have access and 87 percent say cannabis has therapeutic value. Only 11 percent called it a gateway drug, and two percent called it very dangerous.
Why it matters: Emergency clinicians see patients at their sickest, so their views carry weight. Broad support for medical cannabis among these frontline workers suggests growing acceptance in mainstream medicine. The authors also flag knowledge gaps and low clinical confidence, which means patients may still meet providers who lack firm guidance on cannabis-related care.
Read moreSource: norml.org
Medical · November 13, 2026
Brazil's medical cannabis market is booming, according to consulting firm Close-Up International. Sales hit about US$90 million in the 12 months to August 2026, up 15% on the prior year and more than four times the August 2022 level. Pharmacy sales volume rose 31%, prescriptions climbed 37.9%, and unit prices fell roughly 11%.
Why it matters: Brazil is a US-adjacent signal of where regulated medical markets head: more prescribers, more competition from big drugmakers and cheaper products. Patients there gain from falling unit prices, but doctor turnover and import dependence show access is still uneven. New domestic cultivation rules could shift supply, though strict oversight remains in place.
Read moreSource: High Times
Medical · New York · November 12, 2026
A study in the Journal of Addiction Medicine found medical cannabis patients were far likelier to quit prescription opioids. Researchers tracked 8,353 chronic pain patients on long-term opioid therapy for three months, with nearly 5,000 using authorized cannabis. Discontinuation ran two to three times higher among cannabis users, especially those on lower opioid doses.
Why it matters: The findings add to evidence that medical cannabis may help some chronic pain patients cut back on opioids, particularly those on lower doses. It does not show cannabis works for everyone or that stopping opioids is right for any individual. Patients and prescribers weighing options may see this as support for cannabis as an alternative therapy.
Read moreSource: NORML
Medical · California · November 12, 2026
Frequent cannabis use is linked to a lower chance of a glaucoma diagnosis, according to a case-control study in the Journal of Glaucoma. University of California San Diego researchers compared over 5,000 patients with over 20,000 controls and found marijuana use tied to lower odds of primary open-angle glaucoma, with the effect growing alongside use.
Why it matters: The finding is an association, not proof that cannabis protects eyes, and the authors call only for more research into cannabis components as add-on therapies. Cannabis is known to lower eye pressure only temporarily, and the American Glaucoma Society still does not endorse it as treatment, so patients should not read this as a green light.
Read moreSource: NORML
The week in cannabis, in five minutes.Free, every week, from The Pot Report.
Get the Report
Medical · California · November 12, 2026
A survey of 1,023 adult consumers shows people looking for cannabis information put little faith in government sources. Researchers from UC San Francisco and Johns Hopkins found dispensary staff and healthcare providers rated most trustworthy, followed by friends and family. Social media users ranked last, and state and federal officials landed near the bottom.
Why it matters: Public health agencies that want to reach cannabis consumers have a credibility problem, according to these results. People are getting their information at the counter and in the clinic, so the accuracy of what budtenders and doctors say carries real weight. Patients seeking therapeutic guidance mostly lean on healthcare providers, not official websites or campaigns.
Read moreSource: NORML
Medical · November 12, 2026
A survey of Canadian emergency room doctors and nurses found strong backing for medical cannabis. In the BMC Emergency Medicine study, 96 percent said eligible patients should have access, and 87 percent said cannabis has therapeutic value. Just 11 percent called it a gateway drug, and two percent called it very dangerous.
Why it matters: Emergency clinicians see patients at their worst moments, so their views carry weight. Favorable attitudes could make medical cannabis users less likely to face skepticism in urgent care. The authors, though, found gaps in knowledge and clinical confidence, which suggests care for cannabis users in emergency settings may stay uneven until clearer guidelines and training exist.
Read moreSource: NORML
Medical · Pennsylvania · November 12, 2026
Pennsylvania is building a reputation for medical marijuana research, with Philadelphia hosting five of the state's 10 certified academic clinical research centers. Researchers at Jefferson, Drexel and PCOM are studying pain, insomnia and anxiety among the more than 400,000 approved patients, using observational methods because federal limits make randomized trials hard.
Why it matters: Patients now get little hard evidence on which products work for which conditions. Pennsylvania's research centers aim to fill that gap, and Jefferson's Brooke Worster says their findings could add conditions to the state's qualifying list. They may also challenge the belief that more THC means more relief, as researchers warn about high-potency products.
Read moreSource: phillymag.com
Medical · Ohio · November 12, 2026
Researchers at Ohio State University have published a protocol for a pilot trial testing cannabis for sleep disturbance in palliative care. Fifty new cancer patients at the university's comprehensive cancer center will get either usual care or a nightly gummy with 5 mg THC and 5 mg CBD for 30 days. Enrollment is planned from October 2026 to September 2027.
Why it matters: Sleep is the most common reason adults with cancer say they use cannabis, yet solid evidence is thin and most earlier work used pharmaceutical preparations. A trial built around a low-dose gummy, closer to real-world products, could eventually give patients and doctors firmer safety and dosing data. This pilot only tests feasibility and early signals, not proof.
Read moreSource: journals.plos.org